enGene Therapeutics Stock Forecast
NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ENGN analyst consensus
Consensus (10 analysts)
none
Avg. price target
$3.29+84.83%
- Strong buy 1
- Buy 2
- Hold 6
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering enGene Therapeutics (2026-10-09), 3 rate the stock a buy or strong buy, 6 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $3.29, with a high estimate of $5.00 and a low estimate of $2.00. The average target implies upside of 84.8% from the current price of $1.78.
The spread between the highest and lowest targets is 150.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ENGN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 10% |
| Buy | 2 | 20% |
| Hold | 6 | 60% |
| Sell | 1 | 10% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.00 | +12.36% |
| Average target | $3.29 | +84.83% |
| High target | $5.00 | +180.90% |